Esmolol Hydrochloride

Atrial Fibrillation, Rapid Heartbeat, Sinus Tachycardia + 5 more
Treatment
20 Active Studies for Esmolol Hydrochloride

What is Esmolol Hydrochloride

EsmololThe Generic name of this drug
Treatment SummaryEsmolol, also known by the brand name Brevibloc, is a medication that slows down the heart rate and reduces the force of heart contractions. It works by blocking the action of two chemicals, epinephrine and norepinephrine, and it has a fast onset but short duration of action. It is mostly used in medical settings to treat rapid heart rates and is generally safe and effective at recommended doses.
Esmolol Hydrochlorideis the brand name
Esmolol Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Esmolol Hydrochloride
Esmolol
1986
49

Effectiveness

How Esmolol Hydrochloride works in the bodyEsmolol is a type of drug called a beta-blocker. It works by blocking the effects of certain chemical messengers in the body. This decreases the activity of the heart, which can be useful in treating certain irregular heartbeats. Esmolol is more selective than some other beta-blockers, meaning that it mainly affects the heart and not other organs. At normal doses, it does not cause any additional stimulation of the heart. This makes it useful for treating arrhythmias, which are abnormal heart rates.

When to interrupt dosage

The recommended dosage of Esmolol Hydrochloride is contingent upon the determined condition, such as Supraventricular Tachycardia (SVT), heart rate irregularity and peri-operative period. The dosage depends upon the administration method (e.g. Liquid - Intravenous or Liquid) provided in the table underneath.
Condition
Dosage
Administration
Rapid Heartbeat
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Sinus Tachycardia
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Hypertensive disease
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Atrial Fibrillation
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Tachycardia, Supraventricular
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Tachycardia, Ventricular
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
peri-operative period
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous
Arrhythmias, Cardiac
10.0 mg/mL, , 20.0 mg/mL, 250.0 mg/mL
, Intravenous, Injection, solution, Injection, solution - Intravenous, Injection - Intravenous, Injection, Solution, Solution - Intravenous, Liquid, Liquid - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous

Warnings

Esmolol Hydrochloride Contraindications
Condition
Risk Level
Notes
Shock, Cardiogenic
Do Not Combine
Sinus Bradycardia
Do Not Combine
Heart Block
Do Not Combine
Heart failure
Do Not Combine
There are 20 known major drug interactions with Esmolol Hydrochloride.
Common Esmolol Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Esmolol.
4-Methoxyamphetamine
Major
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Esmolol.
Abediterol
Major
The therapeutic efficacy of Abediterol can be decreased when used in combination with Esmolol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Esmolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Esmolol.
Esmolol Hydrochloride Toxicity & Overdose RiskOverdosing on Digoxin can lead to serious conditions such as cardiac arrest, slow heart rate, low blood pressure, and loss of consciousness.
image of a doctor in a lab doing drug, clinical research

Esmolol Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Esmolol Hydrochloride?

Currently, 243 active clinical trials are examining the potential of Esmolol Hydrochloride to regulate aberrant ventricular rate, Flutter, Atrial arrhythmia and peri-operative period.
Condition
Clinical Trials
Trial Phases
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Sinus Tachycardia
0 Actively Recruiting
Tachycardia, Ventricular
0 Actively Recruiting
Arrhythmias, Cardiac
0 Actively Recruiting
peri-operative period
0 Actively Recruiting
Tachycardia, Supraventricular
0 Actively Recruiting
Rapid Heartbeat
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3

Esmolol Hydrochloride Reviews: What are patients saying about Esmolol Hydrochloride?

4.3Patient Review
6/4/2009
Esmolol Hydrochloride for Having a Rapid Heart Action - Supraventricular Tachycardia
This drug, in combination with atrial lead wire placement, saved my father's life. He had a massive AMI on 5-10-09 and was experiencing recurrent VT and VFib afterwards. The medication has been working great so far; as of 06-03-09, he is doing much better.

Patient Q&A Section about esmolol hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is esmolol used for?

"Esmolol is used to control rapid heartbeats or abnormal heart rhythms. This medicine is also used to treat fast heartbeat and high blood pressure during surgery, after surgery, or during other medical procedures."

Answered by AI

What does esmolol do to the heart?

"This medicine is a beta-blocker. It affects the response to nerve impulses in certain parts of the body, such as the heart. As a result, the heart beats slower and decreases the blood pressure."

Answered by AI

What drug class is esmolol?

"Esmolol is a short-acting, cardio-selective beta-blocker that works by antagonizing the beta-1-adrenergic receptors primarily in the myocytes."

Answered by AI

How long does it take esmolol to work?

"If no loading doses are given, it will take about 30 minutes for the effects of esmolol to reach a steady state."

Answered by AI

Clinical Trials for Esmolol Hydrochloride

Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Have you considered Esmolol Hydrochloride clinical trials? We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Mission Cardiovascular Research Institute in Fremont, United States.

REGN7508 + REGN9933 for Atrial Fibrillation

18+
All Sexes
Fremont, CA
This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how well REGN7508 and REGN9933 work in patients that get medicine for their atrial fibrillation. The bleeding effects of REGN7508 and REGN9933 will be compared to another medicine (apixaban), which is available on the market to treat and prevent formation of blood clots. The study is looking at several other research questions, including: * What side effects may happen from taking REGN7508 or REGN9933 * How well do the study drugs reduce the risk of having a stroke * How much of REGN7508 or REGN9933 is in the blood at different times * Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the drugs less effective or could lead to side effects)
Phase 2
Recruiting
Mission Cardiovascular Research Institute (+4 Sites)Clinical Trial ManagementRegeneron Pharmaceuticals
Image of University of Alabama at Birmingham in Birmingham, United States.

Dietary Interventions for Hypertension

18+
All Sexes
Birmingham, AL
Natriuretic peptides (NPs) are hormones produced by the heart and play an important role in maintaining cardiovascular health and have favorable metabolic benefits. Low NP levels are associated with an increased likelihood of the development of cardiometabolic diseases like diabetes and hypertension. NP levels are known to be highly heritable, with up to half of the differences in NP levels being explained by genetics. The investigators aim to describe the genetic architecture of NPs by examining the genetic variants associated with NPs, and generate and validate a polygenic score (PGS) for NPs. The investigators will use this NP PGS to examine the association of genetically determined NP levels with cardiometabolic and cardiovascular outcomes. The investigators will conduct a genotype-guided physiological clinical trial that aims to assess the genetic factors affecting NP levels and their impact on blood pressure and NP response to saline infusion, high-salt diet, and low-salt diet. These findings will help support personal medicine approaches to lower the increasing burden of hypertension in the United States.
Waitlist Available
Has No Placebo
University of Alabama at BirminghamPankaj Arora, MD, FAHA
Have you considered Esmolol Hydrochloride clinical trials? We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of The Cleveland Clinic in Cleveland, United States.

Metabolic Surgery for Atrial Fibrillation

18 - 80
All Sexes
Cleveland, OH
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is estimated that between 3 and 6 million Americans are currently living with AF, while 12 million people in the United States will have AF in 2030. Obesity and its comorbidities such as type 2 diabetes (T2DM), hypertension, and obstructive sleep apnea (OSA) are major risk factors for development and progression of AF. Metabolic and Bariatric Surgery (MBS) is the most effective currently available treatment for obesity. Patients typically lose 20 to 35 percent of body weight after surgery which is often sustained for many years. MBS can improve all 5 major risk factors of AF including obesity, hypertension, T2DM, OSA, and systemic inflammation. The purpose of the study is to understand if MBS can affect the severity of AF and the toll AF's symptoms take on patients.
Phase 4
Waitlist Available
The Cleveland ClinicAli AminaniEthicon, Inc.
Image of The Ottawa Hospital Civic Campus in Ottawa, Canada.

Cardiac CT Angiography for Atrial Fibrillation and Flutter

18+
All Sexes
Ottawa, Canada
The goal of this randomized clinical trial is to learn whether patients with symptomatic atrial fibrillation or atrial flutter (AF) who require heart imaging to rule out a blood clot before cardioversion would benefit from cardiac computed tomography angiography (CCT) in the emergency department (ED) compared to current standard of care management. This will be a multicenter trial evaluating whether CCT-facilitated cardioversion in the ED reduces hospital admission, reduces repeat presentations to hospital and improves patient quality of life compared to the current standard of care. Participants will undergo CCT-facilitated cardioversion or be treated according to current standard of care while in the ED and complete quality of life questionnaires in the ED and follow-up at 30 days.
Waitlist Available
Has No Placebo
The Ottawa Hospital Civic CampusBenjamin Chow, MD PhD FRCPC FACC FESC FA
Image of UCSF Medical Center at Parnassus in San Francisco, United States.

Alcohol Abstinence for Atrial Fibrillation

18+
All Sexes
San Francisco, CA
Per the 2021 National Survey on Drug Use and Health administered by the U.S. Department of Health and Human Services, 85% of all American adults consume alcohol. Atrial fibrillation (AF) is the most common arrhythmia, affecting more than 10 million individuals in U.S., comprising 4.5% of the adult population. Although alcohol abstinence clearly reduces AF in heavy drinkers, observational data comparing the health effects of limited consumption versus abstention are conflicting. The Mediterranean diet is one of the few that has demonstrated clear cardiovascular benefits in a randomized study-this diet allows for the consumption of red wine (or high polyphenol/ low alcohol alcohol), generally not more than one drink in 24 hours, with meals, avoiding spirits and binge drinking. The effect of the "Mediterranean drinking pattern" on AF risk compared to alcohol abstinence remains unknown. This single center, randomized, controlled trial aims to compare the effects of a digital health intervention to encourage durable alcohol abstinence versus allowing guideline-adherent moderate alcohol consumption on AF severity. The knowledge gained from this study may be used to determine optimal thresholds for alcohol use among AF patients.
Recruiting
Has No Placebo
UCSF Medical Center at ParnassusGregory M Marcus, MD, MAS
Have you considered Esmolol Hydrochloride clinical trials? We made a collection of clinical trials featuring Esmolol Hydrochloride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security